Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immediate early response 3-interacting protein 1 (IER3IP1)
- Target
- IER3IP1
- Molecular classification
- Other (ER membrane protein)
01
Overview
Immediate early response 3-interacting protein 1 (IER3IP1) is a small, evolutionarily conserved endoplasmic reticulum (ER) membrane protein encoded by the IER3IP1 gene in humans[1][2][3]. IER3IP1 contains two predicted transmembrane domains and is highly expressed in tissues such as the brain and the endocrine pancreas (notably in β-cells)[2][3]. It plays a crucial role in the ER stress response, cell differentiation, and apoptosis, and is essential for the maintenance of ER homeostasis, particularly in developing neurons and insulin-producing β-cells[1][2][3]. Loss of IER3IP1 disrupts the trafficking and processing of ER and secretory pathway proteins (e.g., FGFR3, UNC5B, SEMA4D), leading to cellular dysfunction and distension of the ER[2]. Mutations in IER3IP1 cause microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS1), indicating its importance in normal brain and pancreatic development[2][3]. IER3IP1 is not a classic drug target such as a receptor or enzyme, and no drugs are reported to currently target it[1][2][3][4].
- Other names
- HSPC039MEDSPRO2309immediate early response 3 interacting protein 1
02
Biological functions
Endoplasmic reticulum stress responseER-to-Golgi protein traffickingCell differentiationApoptosisCell proliferation (especially in neuronal and pancreatic β-cells)
03
Disease associations
Microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS, aka MEDS1)Neurodevelopmental diseaseDiabetes (including neonatal and type 2 diabetes)Epilepsy
04
Safety considerations
Mutations may cause severe neurodevelopmental and endocrine disorders, but no specific drug safety concerns noted
Beyond the preview
Go deeper on Immediate early response 3-interacting protein 1 (IER3IP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immediate early response 3-interacting protein 1 (IER3IP1).